Avui, dijous 7 de maig, el Dipòsit Digital no estarà operatiu per tasques d'actualització. Disculpeu les molèsties.
Hoy, jueves 7 de mayo, el Dipòsit Digital no estará operativo debido a tareas de actualización. Disculpen las molestias.
Today, Thursday, May 7th, the Digital Repository will be unavailable due to a system update.

Fitxers

1-s2.0-S0001731025003035-main.pdf (1.01 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-05-20

Llicència de publicació

cc by-nc-nd (c) Ceravalls Sanchez, Joan et al, 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/223123

Redefiniendo la retirada de omalizumab en pacientes con urticaria crónica espontánea: el valor de la optimización y de los biomarcadores de recurrencia

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.ad.2025.05.004

Resum

Background: Patients with chronic spontaneous urticaria frequently relapse after discontinuing omalizumab and require its reintroduction. Although prior optimization might reduce recurrences, there is scarce evidence on this issue. Moreover, predictors of relapse have been identified in non-optimized patients before suspension. Methods: We conducted a multicenter retrospective study with patients who discontinued omalizumab after optimization with a 12-month follow-up. Univariate and multivariate (tree classification method and Cox regression) analyses were performed. Results: A total of 131 patients were included, 32.8% of whom relapsed after 12 months. Relapsed patients had longer disease duration (24.00 vs 11.00 months; p = 0.032), quicker response to standard dosage (1.00 vs. 3.00 months; p = 0.014), fewer complete responses pre-optimization (83.70% vs 95.50%; p = 0.023), and shorter treatment duration at 300 mg/4 weeks (6 vs 7 months; p = 0.035). Multivariate analysis revealed that patients with elevated baseline C-reactive protein (CRP) and low total immunoglobulin E (IgE) who underwent prolonged treatment were more likely to maintain a sustained remission at 12 months. Conclusion: Optimization seems to reduce the relapse rate after discontinuation. The most relevant factors for recurrence are associated with the duration of treatment at different doses of omalizumab, along with the baseline CRP and total IgE levels. To minimize relapse after suspension, a 12-month treatment regimen at 300 mg/4 weeks followed by an 18-month dose tapering is proposed. (c) 2025 AEDV. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Matèries

Urticària, Antihistamínics

Matèries (anglès)

Urticaria, Antihistamines

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

CERAVALLS SANCHEZ, Joan, et al. Redefiniendo la retirada de omalizumab en pacientes con urticaria crónica espontánea: el valor de la optimización y de los biomarcadores de recurrencia. Actas Dermo-Sifiliográficas. 2025. Vol. 116, núm. 7, pàgs. T675-T683. ISSN 1578-2190. [consulta: 8 de maig de 2026]. Disponible a: https://hdl.handle.net/2445/223123

Exportar metadades

JSON - METS

Compartir registre